Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezacitabine and oxaliplatin in metastatic colorectal cancer
NCT00051688Phase 2Terminated
- Sponsor
- Chiron Corporation
- Start
- Jun 2003
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tezacitabine in colorectal cancer (metastatic) (mCRC), sponsored by Chiron Corporation. Primary endpoint: Maximum Tolerated Dose. Started Jun 2003; status: terminated.
02
Drugs
tezacitabine
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00051688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051688.